Text Size:AAA

IFNA5 / IFNaG Antibody, Rabbit PAb

DatasheetReviewsProtocols
Description: Active  
Expression host: Human Cells  
  • Slide 1
10342-H01H-50
10342-H01H-5
10342-H01H-100
50 µg 
5 µg 
100 µg 
Add to Cart
Expression host: Human Cells  
  • Slide 1
51126-M02H-50
51126-M02H-100
50 µg 
100 µg 
Add to Cart
Expression host: Human Cells  
  • Slide 1
51126-M08H-50
51126-M08H-100
50 µg 
100 µg 
Add to Cart
Expression host: Yeast  
  • Slide 1
80205-R08Y-20
80205-R08Y-100
20 µg 
100 µg 
Add to Cart
Description: Active  
Expression host: Human Cells  
  • Slide 1
80205-R08H-50
80205-R08H-5
80205-R08H-100
50 µg 
5 µg 
100 µg 
Add to Cart

IFNA5/IFNaG AntibodyRelated Products

Related Products

Featured Reagent Products

IFNA5/IFNaG antibody Background

Interferon, alpha 5 (IFNA5) belongs to the alpha/beta interferon family. IFNA5 is the only IFNA subtype detected in normal liver, while a mixture of subtypes is observed in the liver tissue of patients with chronic hepatitis C. Interferons are produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. IFN-alpha, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of growth and differentiation, affecting cellular communication and signal transduction pathways as well as immunological control. Originally discovered as an antiviral substance, the efficacy of IFN-alpha in malignant, viral, immunological, angiogenic, inflammatory, and fibrotic diseases suggests a spectrum of interrelated pathophysiologies. IFN-alpha emerged as a prototypic tumor suppressor protein that represses the clinical tumorigenic phenotype in some malignancies capable of differentiation.

Mouse IFNA5/IFNaG antibody References
  • Lau JY, et al. (1993) Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet. 342(8881): 1208-9.
  • Kessler DS, et al. (1990) Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev. 4(10): 1753-65.
  • Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 91(4): 1198-205.
  • Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"